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poptosis is deﬁned on the basis of morphological
changes like nuclear fragmentation and chromatin
condensation, which are dependent on caspases.
Many forms of caspase-independent cell death have been
reported, but the mechanisms are still poorly understood.
We found that hypoxic cell death was independent of cas-
pases and was associated with signiﬁcant nuclear shrink-
 
age. Neither Bcl-2 nor Apaf-1 deﬁciency prevented
hypoxic nuclear shrinkage. To understand the molecular
mechanism of the nuclear shrinkage, we developed an in
vitro system using permeabilized cells, which allowed us
A
 
to purify a novel member of the phospholipase A
 
2
 
 (PLA
 
2
 
)
 
family that induced nuclear shrinkage. Puriﬁed PLA
 
2
 
 induced
nuclear shrinkage in our permeabilized cell system. PLA
 
2
 
inhibitors prevented hypoxic nuclear shrinkage in cells and
cell death. Hypoxia caused elevation of PLA
 
2
 
 activity and
translocation of intracellular PLA
 
2
 
s to the nucleus. Knock-
 
down of the Ca
 
2
 
 
 
-independent PLA
 
2
 
 delayed nuclear
shrinkage and cell death. These results indicate that Ca
 
2
 
 
 
-
independent PLA
 
2
 
 is crucial for a caspase-independent cell
death signaling pathway leading to nuclear shrinkage.
 
Introduction
 
Apoptosis, or programmed cell death, is a fundamental
biological process that eliminates unwanted cells; it plays a
crucial role in various events, including morphogenesis during
normal development and maintenance of homeostasis.
Apoptosis is defined on the basis of morphological changes
such as chromatin condensation, nuclear fragmentation, and
formation of apoptotic bodies, all of which are driven by a
specific family of proteases called caspases (Salvesen and Dixit,
1997). Several molecules involved in apoptotic nuclear
changes have been identified, including CAD (Enari et al.,
1998; Samejima et al., 2001), acinus (Sahara et al., 1999),
apoptosis-inducing factor (AIF; Susin et al., 1999), and cas-
pase-6 (Ruchaud et al., 2002), although the molecular
mechanisms underlying these morphological changes have
not been elucidated.
Caspase-independent cell death has recently been attracting
more interest. This type of cell death can be induced by
agents that also induce apoptosis under different circum-
stances, such as nitric oxide (Okuno et al., 1998), Bax over-
expression (Xiang et al., 1996), NGF deprivation (Chang
and Johnson, 2002), and hypoxia (Shimizu et al., 1996a).
Cells that are deficient in Apaf-1 or caspases, which are both
essential for apoptosis, undergo death in a caspase-independent
manner (Cheng et al., 2001). However, the morphological
features of caspase-independent cell death vary depending
on the death stimulus or cell type, and several descriptive
terms have been suggested such as necrosis, oncosis, paraptosis,
aponecrosis, and autophagic cell death (Leist and Jaattela,
2001; Lockshin and Zakeri, 2002). We found that nuclear
 
shrinkage is one of the features of caspase-independent cell death
caused by hypoxia. Nuclear shrinkage (pyknosis) has already
been noticed as a feature of hypoxic or ischemic caspase-
independent cell death associated with swelling of organelles,
vacuolization, and increased membrane permeability (Grune
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et al., 1997; Hossmann et al., 2001). EM has revealed that
nuclear pyknosis is associated with condensation of the chro-
matin into many uneven and irregular clumps that are readily
distinguishable from the small number of uniformly dense
and regular aggregates produced by apoptotic chromatin con-
densation (Martin et al., 1998).
Phospholipase A
 
2
 
 (PLA
 
2
 
) comprises a family of esterases
that hydrolyze the 
 
sn-2
 
 ester bond in phospholipids to re-
lease free fatty acids and lysophospholipids. A number of
mammalian PLA
 
2
 
 isotypes have been identified, and are di-
vided into three major subfamilies: secretory PLA
 
2
 
 (sPLA
 
2
 
),
cytosolic Ca
 
2
 
 
 
-dependent PLA
 
2
 
 (cPLA
 
2
 
), and Ca
 
2
 
 
 
-inde-
pendent PLA
 
2
 
 (iPLA
 
2
 
; Six and Dennis, 2000; Ma and Turk,
2001). sPLA
 
2
 
s are extracellular low molecular mass enzymes
(14 kD) that require millimolar concentrations of Ca
 
2
 
 
 
 for
activation. sPLA
 
2
 
s are thought to be potent mediators of in-
flammation and also show antibacterial activity. cPLA
 
2
 
s are
intracellular enzymes that specifically target arachidonic acid
(AA) at the 
 
sn-2
 
 position of phospholipids. Their activity is
regulated by submicromolar levels of Ca
 
2
 
 
 
, and these en-
zymes are believed to play a pivotal role in the production of
AA metabolites, such as eicosanoids. The activity of iPLA
 
2
 
 is
Ca
 
2
 
 
 
-independent, and it is thought to be a remodeling en-
zyme that maintains the composition of membrane phos-
pholipids. Although the molecular basis of caspase-indepen-
dent cell death is largely unknown, PLA
 
2
 
s have been
implicated in ischemic cell death; however, their actual role
remains unclear (Bazan and Rodriguez de Turco, 1980;
Edgar et al., 1982). In addition, it has been reported that
some PLA
 
2
 
 inhibitors can prevent ischemic cell death (Wang
et al., 1996; Arai et al., 2001; Michiels et al., 2002; Williams
and Gottlieb, 2002), and that cPLA
 
2
 
 
 
-deficient mice show
partial resistance to ischemic cell death (Bonventre et al.,
1997). However, the molecular mechanism of the morpho-
logical changes that occur during hypoxia is unknown.
Here, we report that PLA
 
2
 
 is responsible for nuclear shrink-
age in the process of caspase-independent cell death.
 
Results
 
Hypoxia induces nuclear shrinkage in a caspase- and 
Apaf-1–independent and Bcl-2–insensitive manner
 
To understand the molecular basis of caspase-independent
cell death, we focused on nuclear shrinkage as a starting point
for analysis because it is known to be often associated with
caspase-independent cell death. By screening various culture
conditions, we found that PC12 cells subjected to hypoxia in
the presence of a low glucose concentration (such as 2.2 g/l)
reproducibly showed nuclear shrinkage without chromatin
fragmentation (Fig. 1 A). Therefore, we cultured the cells with
Figure 1. Hypoxic nuclear shrinkage is 
caspase- and Apaf-1–independent, and 
Bcl-2–insensitive. (A) PC12 cells were 
incubated under normoxic conditions (a) 
or hypoxic conditions for 36 h in the 
absence (b and c) or presence (d) of 50  M 
zVAD-fmk. PC12 cells were also treated 
with 1  M staurosporine (STS) for 14 h 
in the absence (e) or presence (f) of 50  M 
zVAD-fmk. (B) PC12 cells were treated 
as in A. Cell lysates were subjected to 
Western blot analysis with an antibody 
for lamin B1 (top), and caspase activity 
was measured (bottom). (C) Apaf-1
 /  
MEFs were cultured under normoxic (a) 
or hypoxic (b) conditions for 40 h. (D) 
PC12 cells stably transfected with Bcl-2 
DNA (d–f) or control vector DNA (a–c) 
were incubated under normoxic (a and d) 
or hypoxic (b and e) conditions for 36 h, 
or were treated with 1  M STS for 14 h 
(c and f). Nuclei were stained with 
Hoechst 33342 together with (or without) 
propidium iodide and then visualized 
under a fluorescence microscope. 
Arrows in A indicate apoptotic nuclei. 
Bars, 10  m. 
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2.2 g/l glucose for this experiment. When stained with pro-
pidium iodide, shrunken nuclei also incorporated the dye
(Fig. 1 A, b), demonstrating the loss of membrane integrity
that is a characteristic of necrotic death. A pan-caspase inhibi-
tor (zVAD-fmk) had no effect on nuclear shrinkage (Fig. 1 A,
c and d), whereas apoptotic nuclear changes such as chroma-
tin condensation and fragmentation induced by staurosporine
(STS) were completely prevented by zVAD-fmk (Fig. 1 A, e
and f), indicating that caspases were not involved in the pro-
cess of hypoxia-induced nuclear shrinkage. Also, we could not
detect caspase-3 activity and caspase-dependent cleavage of
lamin B1 to a 30-kD fragment under hypoxia (Fig. 1 B). To
further confirm the caspase independence of nuclear shrink-
age, we used mouse embryonic fibroblasts (MEFs) from Apaf-
1–deficient mice. Apaf-1 has been shown to be essential for
mitochondria-dependent caspase activation in the intrinsic
death pathway (Cecconi et al., 1998; Yoshida et al., 1998).
Upon exposure to hypoxia, Apaf-1
 
 
 
/
 
 
 
 MEFs showed nuclear
shrinkage (Fig. 1 C), confirming the independence of hypoxic
 
nuclear shrinkage from the caspase cascade. This result also
demonstrated the occurrence of hypoxic nuclear shrinkage in
a different type of cell. Because it has been reported that Bcl-2
not only inhibits apoptosis, but also caspase-independent cell
death (Monney et al., 1998; Okuno et al., 1998; Haraguchi et
al., 2000), we examined whether Bcl-2 could protect against
hypoxic nuclear shrinkage using Bcl-2–overexpressing PC12
cells. As shown in Fig. 1 D (e), Bcl-2 had no inhibitory effect
on nuclear shrinkage, although apoptotic nuclear changes
were completely prevented in the Bcl-2–overexpressing cells
(Fig. 1 D, f). These results showed that hypoxic nuclear
shrinkage was induced by a caspase- and Apaf-1–independent
mechanism that was Bcl-2–insensitive.
 
Nuclear shrinkage assay and purification of a nuclear 
shrinkage factor from rat liver
 
To identify a molecule that induced nuclear shrinkage, we de-
veloped an in vitro assay system using digitonin-permeabi-
lized cells. Permeabilized HeLa cells were incubated with a ly-
Figure 2. Detection of nuclear shrinkage 
factor in cell lysates using the perme-
abilized cell system. (A) HeLa cells were 
permeabilized with digitonin as described 
in Materials and methods, and then were 
incubated for 2 h with buffer (a), hypoxic 
PC12 cell lysate (b), or normoxic PC12 
cell lysate (c). (B) Permeabilized HeLa 
cells were incubated for 2 h with buffer 
(a), rat liver S100 with (b) or without (c) 
zVAD-fmk, or rat mitochondrial super-
natant (d). Nuclei were visualized under 
a fluorescence microscope after staining 
with Hoechst 33342. Bars, 10  m. 
(C) Illustration of the purification steps 
for nuclear shrinkage factor. Proteins 
bound to each column were applied to 
the next column, except that the flow-
through (FT) fractions were used in the 
case of the heparin column. (D) Aliquots 
of Mini Q™ column fractions were 
added to digitonin-permeabilized HeLa 
cells and incubated for 2 h at 37 C, 
followed by Hoechst 33342 staining. 
Under a fluorescence microscope, the 
morphology of  500 nuclei was observed, 
and the percentage of cells showing 
nuclear shrinkage was assessed. (E) 
Aliquots of Mini Q™ column fractions 
were subjected to 15% SDS-PAGE and 
silver staining. The amino acid sequences 
of the proteins indicated by arrows were 
determined. 
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sate prepared from hypoxic PC12 cells. As shown in Fig. 2 A,
the lysate induced nuclear shrinkage, indicating that this per-
meabilized cell system could reproduce the shrinkage that oc-
curred in cultured cells. However, a lysate from normoxic
PC12 cells also induced nuclear shrinkage to a similar extent
(Fig. 2 A, c). This was due to activation of PLA
 
2
 
 by disruption
of the cells (see Fig. 6). To obtain a large volume of starting
material, we examined whether rat liver S100 lysate could in-
duce nuclear shrinkage using the permeabilized cell system.
We found that this lysate induced nuclear shrinkage in a cas-
pase-independent manner (Fig. 2 B, b and c). The lysate-
induced nuclear shrinkage was morphologically distinct from
the nuclear changes induced by rat mitochondrial superna-
tant, which possibly contained AIF activity (Fig. 2 B, d). AIF
induced peripheral chromatin condensation, as described
elsewhere (Susin et al., 2000), whereas liver S100 or PC12 ly-
sate induced homogeneous nuclear condensation, indicating
the presence of an unidentified factor. A nuclear shrinkage
factor was partially purified by seven steps of column chroma-
tography, as shown in Fig. 2 C. Two proteins, shown by ar-
rows in Fig. 2 E, were found to be closely associated with
nuclear shrinkage (Fig. 2 D). After lysine endopeptidase
digestion and separation on a reverse-phase HPLC column,
the amino acid sequences of proteins 1 and 2 were deter-
mined. Protein 1 was rat UDP-
 
N
 
-acetylglucosamine 2-epi-
merase, which is a liver-specific protein with a predicted mo-
lecular mass of 79 kD that is associated with the biosynthesis
of 
 
N
 
-acetylneuraminic acid (Stasche et al., 1997). However,
 
the fact that hypoxic nuclear shrinkage was not tissue specific
suggested that UDP-
 
N
 
-acetylglucosamine 2-epimerase was
not the nuclear shrinkage factor. Although the sequences of
four peptides of protein 2 with a predicted molecular mass of
66 kD were determined, we could not find any gene in the
database that encoded these four sequences. Therefore, we at-
tempted to isolate part of the gene by RT-PCR using various
combinations of degenerative primers based on the amino
acid sequences of the four peptides. The amino acid sequence
deduced from the PCR product, which included three of the
four peptides (peptides 1, 3, and 4), is shown in Fig. 3. The
sequences showed significant homology with human cPLA
 
2
 
 
 
(cytosolic PLA
 
2
 
 type 
 
 
 
) and included the lipase consensus se-
quence (GXSXS; Fig. 3), but the carboxy-terminal portion
(aa 255–329) had no homology with human cPLA
 
2
 
 
 
. Hu-
man cPLA
 
2
 
 
 
 is reported to possess calcium-independent
PLA
 
2
 
 activity (Underwood et al., 1998; Pickard et al., 1999).
We have not determined the sequence of the full-length
DNA of protein 2. Subsequently, we found that the mouse
counterpart of protein 2, which was inferred from the mouse
genome database of Celera Genomics, contained the peptide
2 sequence outside the region amplified by PCR.
 
PLA
 
2
 
 activity is necessary for nuclear shrinkage 
in the permeabilized cell system
 
To test whether or not PLA
 
2
 
 activity was a prerequisite for
nuclear shrinkage in the permeabilized cell system, we ex-
amined the effect of intracellular PLA
 
2
 
 inhibitors on the
Figure 3. Alignment of the amino acid 
sequences of protein 2 and human 
cPLA2 . The amino acid sequences of 
the four peptides are shown at the top. 
The amino acid sequence of protein 2, 
which was predicted from the cDNA 
sequence generated by PCR using 
degenerative primers, and that of human 
cPLA2  (hcPLA2 ) were aligned. Identical 
and similar amino acid residues are shown 
by asterisks and dots, respectively. Three 
sequenced peptides that are part of the 
known sequence of protein 2 are under-
lined. The lipase consensus sequence is 
boxed. The degenerative PCR primers 
used to amplify protein 2 cDNA are 
shown by arrows. These sequence data 
are available from GenBank/EMBL/
DDBJ under accession no. AB113213. 
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occurrence of shrinkage. We used three kinds of intracellu-
lar PLA
 
2
 
 inhibitors: methyl arachidonyl fluorophosphonate
(MAFP), bromoenol lactone (BEL), and arachidonyltriflu-
oromethyl ketone (AACOCF
 
3
 
). These inhibitors were
originally thought to be selective for a specific PLA
 
2
 
, but
are now known to also inhibit other isoforms (Balsinde et
al., 1999). When permeabilized HeLa cells were treated
with the HiTrap™ Q Sepharose column-bound fraction
of rat liver S100 lysate, all the inhibitors blocked nuclear
shrinkage in a dose-dependent manner (Fig. 4 A). These
results indicated that PLA
 
2
 
 activity in the rat liver S100 ly-
 
sate was responsible for nuclear shrinkage in our permeabi-
lized cell system.
 
PLA
 
2
 
 induces nuclear shrinkage in the permeabilized 
cell system
 
To investigate whether PLA
 
2
 
 activity alone was sufficient to
induce nuclear shrinkage, bee venom PLA
 
2
 
 (a commercially
available form of purified PLA
 
2
 
) was used. When added to
permeabilized HeLa cells, bee venom PLA
 
2
 
 induced nuclear
shrinkage in a concentration-dependent manner (Fig. 4, B
and C). MAFP inhibited bee venom PLA
 
2
 
-induced nuclear
shrinkage (Fig. 4 B, d; Fig. 4 C, d), although only partially
due to its incomplete inhibition of PLA
 
2
 
 activity (MAFP in-
hibited PLA
 
2
 
 activity by 69.9%). Quantitative measurement
of the nuclear area showed that it was 130.27 
 
 
 
 34.69 
 
 
 
m
 
2
 
for control nuclei and 50.38 
 
 
 
 13.96 
 
 
 
m
2 for the nuclei of
cells treated with 5 ng/ l PLA2. Another type of PLA2 (por-
cine pancreatic sPLA2) also caused nuclear shrinkage like bee
venom PLA2 (unpublished data). Because PLA2 hydrolyzes
phospholipids at the sn-2 position to liberate fatty acids, we
tested whether fatty acids (saturated and unsaturated) could
cause nuclear shrinkage in the permeabilized cell system. AA
(Fig. 4 B, e) and other fatty acids (stearic, linoleic, palmitic,
and oleic acids; unpublished data) had no effect, suggesting
that PLA2 induced nuclear shrinkage itself and that its me-
tabolites were ineffective.
PLA2 activity is essential for nuclear shrinkage 
in hypoxic cells
Because our results showed that PLA2 activity was necessary
and sufficient to induce nuclear shrinkage in permeabilized
cells, we next examined the effect of PLA2 inhibitors on nu-
clear shrinkage in PC12 cells. Some cells developed typical
apoptotic nuclear features in response to hypoxia and PLA2
inhibitor treatment (Fig. 5 A, d), so zVAD-fmk was also
added to the culture medium to prevent apoptosis. The four
PLA2 inhibitors tested (BEL, AACOCF3, MAFP, and pal-
mitoyl trifluoromethyl ketone [PACOCF3]) prevented the
nuclear shrinkage of PC12 cells induced by hypoxia to a
varying extent (Fig. 5 A), indicating that PLA2 activity
plays an important role in hypoxic nuclear shrinkage. BEL
almost completely inhibited nuclear shrinkage, whereas
PACOCF3 only caused partial inhibition (Fig. 5 B). BEL and
PACOCF3 (iPLA2 inhibitors) were more potent than MAFP
and AACOCF3 (cPLA2 inhibitors; Fig. 5 A), suggesting that
iPLA2 plays a major role in hypoxic nuclear shrinkage.
Activation and nuclear translocation of PLA2 
during hypoxia
It has been reported that intracellular PLA2s, including
cPLA2  and iPLA2, undergo translocation from the cyto-
plasm to the nuclear membrane, and PLA2 activity is elevated
in ATP-depleted cells (Arai et al., 2001; Sheridan et al., 2001;
Michiels et al., 2002; Williams and Gottlieb, 2002). We ex-
amined whether PLA2 activity was increased during hypoxia
using the fluorescent PLA2 reporter N-((6-(2,4-dinitrophe-
nyl)amino)hexanoyl)-2-(4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-pentanoyl)-sn-glycero-3-phosphoeth-
anolamine (PED6). In this lipid, the fluorescent BODIPY
®
Figure 4. PLA2 activity is required for nuclear shrinkage of 
permeabilized cells. (A) PLA2 inhibitors prevent rat liver S100-induced 
nuclear shrinkage of permeabilized cells. An aliquot of the fraction 
bound to the HiTrap™ Q column was incubated with permeabilized 
HeLa cells for 2 h at 37 C in the presence or absence of the indicated 
PLA2 inhibitors. The percentage of cells with nuclear shrinkage in two 
independent experiments is shown. (B) Permeabilized HeLa cells 
were exposed to bee venom PLA2 at (a) 0, (b) 1.0, (c) 5.0, or (d) 5.0 
ng/ l together with 66.7  M MAFP, or at 10  M AA (e) for 2 h. 
Nuclei were visualized under a fluorescence microscope after Hoechst 
33342 staining. The average nuclear area is shown under the photo-
graph. Bars, 10  m. (C) The areas of shrunken nuclei were individually 
determined from the fluorescence microscopy images, and the 
percentage of cells with the indicated nuclear size was plotted.1224 The Journal of Cell Biology | Volume 163, Number 6, 2003
moiety at the sn-2 position is quenched by the DNP group in
the head group, but emits fluorescence when released by
PLA2 catalysis (Farber et al., 2001). As shown in Fig. 6 A,
strong BODIPY
® fluorescence was detected in hypoxic cells
with shrunken nuclei, but only weak fluorescence was found
in control cells and BEL/zVAD-fmk–treated cells. However,
when cells were lysed, PLA2 activity was spontaneously in-
creased (Fig. 6 B), explaining that a lysate of normal PC12
also induced nuclear shrinkage (Fig. 2 A, c). To further con-
firm the increase of PLA2 activity during hypoxia, AA release
into the culture medium was measured. AA release was in-
duced by hypoxia, and was inhibited by BEL/zVAD-fmk,
but not by zVAD-fmk (Fig. 6 C). These results showed that
PLA2 activity was increased during hypoxia and then induced
nuclear shrinkage.
Because the distribution of PED6 was not necessarily cor-
related with the subcellular localization of PLA2 activity, we
investigated the localization of intracellular PLA2 proteins
during hypoxia. CHO-k1 cells were used because of the re-
activity of the available anti-iPLA2 antibody. After exposure
to hypoxia, CHO-k1 cells were treated with Triton X-100
for separation into supernatant and pellet fractions that con-
tained cytosolic and nuclear proteins, respectively. Analysis
of the localization of iPLA2 and cPLA2  during hypoxia
showed that these PLA2s translocated to the nucleus from
the cytoplasm within 24 h of hypoxic exposure (Fig. 7 A).
Although a large amount of cPLA2  remained in the cyto-
plasm after exposure to hypoxia, most iPLA2 underwent
translocation to the nucleus. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) protein was observed in the nu-
clear fraction at 35 h, but this may have been due to accu-
mulation of unfolded GAPDH caused by the depletion of
ATP. Accumulation of iPLA2 in the nucleus during hypoxia
was also confirmed by immunostaining with anti-iPLA2 an-
tibody (Fig. 7 B). These results demonstrated that iPLA2 un-
derwent translocation to the nucleus during hypoxia and
that PLA2 activity showed a concomitant increase in the
shrunken nuclei.
Reduction of iPLA2 inhibits hypoxic nuclear shrinkage
To further investigate the importance of iPLA2 for hypoxic
nuclear shrinkage, we reduced the iPLA2 level using small
interfering RNA (siRNA). CHO-k1 cells were treated with
siRNA for iPLA2 or GFP (negative control), and the ex-
Figure 5. PLA2 is essential for nuclear shrinkage 
in hypoxic cells. (A) PC12 cells were incubated un-
der normoxic (a) or hypoxic (b–h) conditions for
36 h. Before hypoxia, 50  M zVAD-fmk (Z) and the 
indicated PLA2 inhibitors were added to the culture 
medium. Nuclei were visualized under a fluores-
cence microscope after Hoechst 33342 staining. 
The average nuclear area is shown under the photo-
graphs. Arrows indicate apoptotic nuclei. Bars, 10 
 m. (B) As described in Fig. 4 C, the percentage of 
cells with the indicated nuclear size was plotted.PLA2 induces nuclear shrinkage | Shinzawa and Tsujimoto 1225
pression of iPLA2 protein was assessed by Western blot-
ting. After transfection with siRNA for iPLA2, the level of
iPLA2 protein decreased significantly in a dose-dependent
manner (Fig. 8 A). As shown in Fig. 8 B, hypoxic nuclear
shrinkage was suppressed in cells treated with siRNA for
iPLA2, but not in cells treated with siRNA for GFP. These
results suggested that iPLA2 plays a major role in hypoxic
nuclear shrinkage.
PLA2 inhibitors and reduction of iPLA2 prevent hypoxic 
cell death
Next, we examined whether PLA2 inhibitors or a reduction
of the iPLA2 level could influence hypoxic cell death. Cell
death was assessed by lactate dehydrogenase (LDH) release
into the culture medium, as described in Materials and
methods. Treatment with BEL partially inhibited hypoxic
cell death in the absence of zVAD-fmk (Fig. 9 A); the
partial inhibition was due to the occurrence of apopto-
sis (Fig. 5 A, d). In the presence of zVAD-fmk, BEL
and PACOCF3 effectively prevented hypoxic cell death,
whereas MAFP and AACOCF3 only partially prevented it
(Fig. 9 A). Moreover, reduction of the iPLA2 level by
siRNA delayed the onset of hypoxic cell death (Fig. 9 B).
These results demonstrated that PLA2 (mainly iPLA2) not
only regulated nuclear shrinkage, but also mediated the
death of hypoxic cells.
BEL also prevents caspase-independent nuclear 
shrinkage induced by other stimuli
We examined whether the inhibitory effect of the PLA2 in-
hibitor BEL on nuclear shrinkage was also applicable to
other types of caspase-independent cell death. PC12 cells
were exposed to STS in the presence of zVAD-fmk. To ac-
celerate caspase-independent death, the glucose concentra-
tion of the culture medium was decreased to 0.9 g/l. Under
these conditions, almost all of the cells showed shrunken nu-
clei after STS and zVAD-fmk treatment for 24 h (Fig. 10 A,
b). BEL inhibited STS-induced nuclear shrinkage, but mar-
ginal chromatin condensation still occurred (Fig. 10 A, c).
Next, primary cultured mouse cerebellar granule neurons
were exposed to a low K
  medium, which induced caspase-
independent death. BEL also partially inhibited nuclear
shrinkage in these cells (Fig. 10 B). The architecture of eu-
chromatin and heterochromatin appeared to remain intact
in BEL/low K
 -treated neurons, but not in low K
 -treated
neurons. These results showed that the PLA2 inhibitor BEL
could prevent nuclear shrinkage in various forms of caspase-
independent death.
Figure 6. Intracellular PLA2 is activated by hypoxia. PC12 cells 
were exposed to hypoxia for 30 h in the absence or presence of a 
PLA2 inhibitor and a caspase inhibitor. Cells were also incubated 
under normoxic conditions. (A) Liposomes containing PED6 
(a fluorescent PLA2 reporter) were prepared as described in Materials 
and methods, added to the culture medium, and incubated for 10 
min. After nuclear staining, fluorescence arising from Hoechst 33342 
(d–f) and from PED6 (a–c) was visualized using a confocal micro-
scope. Bars, 10  m. (B) Before and after disruption of normoxic 
cells, PLA2 activity was measured as described in Materials and 
methods. (C) AA released into the culture medium by hypoxia was 
measured as described in Materials and methods.
Figure 7. Translocation of iPLA2 from cytosol to nucleus during 
hypoxia. (A) CHO-k1 cells were incubated under hypoxic conditions 
for the indicated time. Cells were separated into cytosolic and nuclear 
fractions, and then were subjected to 15% SDS-PAGE followed by 
Western blot analysis. The filter was probed with antibodies for 
iPLA2, cPLA2 , lamin B1, and GAPDH. Lamin B1 (a nuclear protein) 
and GAPDH (a cytoplasmic protein) were used as the controls for 
cell fractionation. (B) CHO-k1 cells were exposed to normoxia (a) 
or hypoxia (b) for 36 h. Then, the cells were immunostained with 
anti-iPLA2 antibody, as described in Materials and methods, and 
visualized under a confocal microscope. Bars, 10  m.1226 The Journal of Cell Biology | Volume 163, Number 6, 2003
Discussion
Nuclear shrinkage associated with caspase-independent 
cell death
A great deal of attention has been focused on caspase-indepen-
dent cell death, which is associated with cell death paradigms
related to nitric oxide, Bax, hypoxia, and NGF deprivation
(Shimizu et al., 1996a; Xiang et al., 1996; Okuno et al., 1998;
Chang and Johnson, 2002). We focused on hypoxic nuclear
shrinkage to investigate the molecular pathway of caspase-
independent cell death. Nuclear shrinkage termed pyknosis
occurs in organ ischemia (Grune et al., 1997; Hossmann et
al., 2001), and we confirmed that almost all cells exposed to
hypoxia developed significant nuclear shrinkage that was me-
diated by a caspase-independent, Apaf-1–independent, and
Bcl-2–insensitive pathway (Fig. 1). This nuclear shrinkage
was also induced by STS in the presence of a caspase inhibitor
for PC12 cells or low K
  for cerebellar granule neurons (Fig.
10), indicating that the occurrence of nuclear shrinkage is not
specific to hypoxia. Because caspase-independent cell death
that is not accompanied by nuclear shrinkage has also been re-
ported (Kawahara et al., 1998; Miyazaki et al., 2001), nuclear
shrinkage is not universal to all types of caspase-independent
cell death. Instead, it is a feature of some kinds of caspase-
independent cell death, including that due to hypoxia, sug-
gesting that there is more than one mechanism of caspase-
independent death.
Essential role of PLA2 in nuclear shrinkage
Using HeLa cells permeabilized by digitonin, we established
an in vitro assay system that allowed the purification of a
factor causing nuclear shrinkage, and we identified a mem-
Figure 8. A reduced iPLA2 level inhibits hypoxic nuclear shrinkage. 
The indicated dose of siRNA for GFP or iPLA2 was transfected into 
CHO-k1 cells three times as described in Materials and methods. 
GFP was used as the negative control. (A) Expression of iPLA2 
protein was assessed by Western blotting. The lysates from GFP 
siRNA- or iPLA2 siRNA-treated CHO-k1 cells were subjected to 
15% SDS-PAGE followed by Western blotting with an antibody 
for iPLA2, lamin B1, or GAPDH (Lamin B1 and GAPDH were 
loading controls). (B) CHO-k1 cells were transfected with siRNA 
for GFP (2  g/well) or siRNA for iPLA2 (6  g/well), and then were 
exposed to normoxia or hypoxia for 36 h. Subsequently, the cells 
were stained with Hoechst 33342 and visualized under a fluores-
cence microscope. Bars, 10  m. Note that siRNA for iPLA2 (2  g/well) 
showed similar results (not depicted). The average nuclear area is 
shown under the photograph.
Figure 9. PLA2 inhibitors or reduction of iPLA2 protein prevents 
hypoxic cell death in the presence of a caspase inhibitor. (A) PC12 
cells were exposed to normoxia or hypoxia for 36 h. The indicated 
inhibitors were added to the culture medium before hypoxia. LDH 
release from the cells was measured as described in Materials and 
methods. (B) As described in Fig. 8, CHO-k1 cells were transfected 
with siRNA for GFP or iPLA2 and were exposed to hypoxia for the 
indicated times. Cell death was then monitored by LDH release.PLA2 induces nuclear shrinkage | Shinzawa and Tsujimoto 1227
ber of the PLA2 family as a nuclear shrinkage factor in rat
liver lysate. The evidence for an essential role of PLA2 in hy-
poxic nuclear shrinkage was as follows: (1) rat cPLA2  and
bee venom PLA2 induced nuclear shrinkage in our perme-
abilized cell system (Fig. 2 D and Fig. 4 B); (2) there was in-
hibition of hypoxic nuclear shrinkage by several PLA2 inhib-
itors (Fig. 5); and (3) there was inhibition of hypoxic nuclear
shrinkage by reduction of the iPLA2 level (Fig. 8). The
mechanism through which PLA2 induces nuclear shrinkage
remains to be determined. Addition of various fatty acids to
permeabilized cells had no effect on nuclear shrinkage, ex-
cluding the direct involvement of its metabolites. Significant
loss of nuclear membrane phospholipids has been reported
during myocardial ischemia, which probably contributes to
nuclear shrinkage (Williams et al., 2000). It has also been re-
ported that bee venom PLA2 induces the shrinkage of eryth-
rocytes independently of an osmotic effect (Rudenko et al.,
1997), and such erythrocyte shrinkage may occur by the
same mechanism as nuclear shrinkage. The nuclear lamina is
important for maintaining the stability of the nucleus and is
cleaved to a 30-kD fragment during apoptosis, leading to
nuclear changes (Ruchaud et al., 2002). During hypoxic
death, the lamina was also cleaved (although at a different
site; Fig. 1 B), and the ring of the nuclear lamina was smaller
in shrunken nuclei (unpublished data). Cleavage of the lam-
ina during hypoxic cell death might have some role in nu-
clear shrinkage. Alternatively, nuclear shrinkage may result
from the loss of mobile components of the nucleus after
breakdown of nuclear membrane by PLA2. EM indicated
that the density of hypoxic shrunken nuclei was decreased
(unpublished data).
AIF was initially purified as a factor released from the mi-
tochondria when the mitochondrial permeability transition
occurred that induced apoptotic changes of the nucleus in a
caspase-independent manner (Susin et al., 1999). Addition
of recombinant AIF protein to purified nuclei induces DNA
loss, peripheral chromatin condensation, DNA fragmenta-
tion into pieces  50 kbp in size, and nuclear shrinkage.
However, the effects of PLA2 and AIF on the nucleus are sig-
nificantly different: AIF induced peripheral chromatin con-
densation (Susin et al., 2000), whereas PLA2 induces homo-
geneous nuclear condensation. Furthermore, the release of
AIF from the mitochondria is inhibited by Bcl-2, but nu-
clear shrinkage still occurred in the presence of Bcl-2. These
results suggest that PLA2 plays a different role in nuclear
changes from that of AIF.
iPLA2 is responsible for nuclear shrinkage
A number of mammalian PLA2 isotypes have been identi-
fied; they are divided into three major subfamilies: sPLA2,
cPLA2, and iPLA2 (Six and Dennis, 2000; Ma and Turk,
2001).
We purified rat cPLA2  as a factor causing nuclear shrink-
age (Fig. 2). We were successful in purifying cPLA2  protein
from among many PLA2 isotypes for the following reasons:
(1) we assayed nuclear shrinkage in the presence of 0.5 mM
EGTA to avoid nonspecific activation of Ca
2 -dependent
proteases, and there are only three known intracellular Ca
2 -
independent PLA2 genes (iPLA2 , iPLA2 , and cPLA2 );
(2) MAFP was most the effective inhibitor of liver S100 ly-
sate-induced nuclear shrinkage (Fig. 4 A); and (3) 10  M
MAFP has been shown to completely suppress recombinant
human cPLA2  (Stewart et al., 2002). Thus, cPLA2  might
be most stable or abundant in the rat liver S100 fraction.
Which isotype of the PLA2 family is responsible for nu-
clear shrinkage in cells? Among several PLA2 inhibitors
tested, BEL was the most potent inhibitor of hypoxic nu-
clear shrinkage in PC12 cells (Fig. 5). Previously, it has been
reported that BEL is a potent and selective inhibitor of all
iPLA2 isotypes, including iPLA2 , iPLA2 , and cPLA2 
(Balsinde et al., 1999; Mancuso et al., 2000; Stewart et al.,
2002). Here, we showed that reduction of iPLA2  using
siRNA could inhibit nuclear shrinkage, and that most
iPLA2  underwent translocation to the nucleus during hy-
poxia. Based on these results, we concluded that iPLA2, but
not cPLA2, plays a major role in hypoxic nuclear shrinkage,
although we could not exclude the possibility that other
PLA2 isoforms may have a role in different circumstances.
PLA2 activation
We found that PLA2 activity was increased and that iPLA2
protein accumulated in the nucleus during hypoxia (Fig. 6
and Fig. 7), changes that probably contributed to nuclear
shrinkage. An increase of PLA2 activity and loss of nuclear
membrane phospholipids during hypoxia or ischemia has
been reported previously (McHowat et al., 1998; Williams
et al., 2000; Arai et al., 2001), but the mechanism of PLA2
Figure 10. Effect of PLA2 inhibitor on nuclear shrinkage induced 
in a caspase-independent manner by other stimuli. (A) Caspase-
independent death of PC12 cells was induced by incubation for 24 h 
with 500 nM STS and 50  M zVAD-fmk in the presence (c) or 
absence (b) of 35  M BEL at a low glucose concentration (0.9 g/l). 
(B) Cerebellar granule neurons were harvested as described in Materials 
and methods. Neurons were cultured for 7 d in medium containing 
10% serum and 25 mM KCl, and caspase-independent cell death 
was induced by replacing this medium with serum-free medium 
containing 5 mM KCl (low K
 ) and incubation for 24 h in the presence 
(c) or absence (b) of 40  M BEL. Nuclei were visualized under a 
fluorescence microscope after Hoechst 33342 staining. Bars, 10  m. 
The average nuclear area is shown under the photograph.1228 The Journal of Cell Biology | Volume 163, Number 6, 2003
activation remains to be elucidated. A decrease of ATP may
trigger PLA2 activation during hypoxia because the activity
of iPLA2 purified from cardiac myocytes was inhibited in the
presence of ATP (McHowat et al., 1998), although there is a
contradictory report that the activity of recombinant iPLA2 
(which has an ATP-binding motif) was augmented in the
presence of ATP (Ma et al., 1999). Another possibility is
that PLA2 activity remains unchanged, but membrane phos-
pholipids might be modified more susceptible to PLA2.
Cell death
A number of authors have reported that PLA2 inhibitors
have a cytoprotective role against various death paradigms
(Wissing et al., 1997; Cummings et al., 2000; Arai et al.,
2001; Williams and Gottlieb, 2002). However, none of
these analyses rigorously assessed whether PLA2 was specifi-
cally involved in caspase-dependent cell death (apoptosis) or
in caspase-independent cell death. Here, we showed that
PLA2 inhibitors could prevent hypoxic cell death in the pres-
ence of a pan-caspase inhibitor (Fig. 9), although the pan-
caspase inhibitor itself was ineffective. How does PLA2 in-
duce cell death? Activated PLA2 may disrupt the nuclear
architecture, thus eventually causing death. Alternatively,
PLA2 releases free fatty acids from phospholipid membranes,
and these may induce the mitochondrial permeability transi-
tion, leading to mitochondrial dysfunction. It is also possible
that PLA2 may directly target and disrupt cellular mem-
branes, thus killing cells.
Materials and methods
Reagents
zVAD-fmk and Ac-DEVD-MCA were purchased from Peptide Institute,
Inc. BEL and MAFP were obtained from Cayman Chemical. AACOCF3 and
PACOCF3 were purchased from Calbiochem. Bee venom PLA2 and AA
were obtained from Sigma-Aldrich. Primary antibodies for iPLA2, cPLA2 
(N-216), GAPDH, and lamin B1 were from Cayman Chemical, Santa Cruz
Biotechnology, Inc., Biogenesis, or Zymed Laboratories, respectively.
Cell culture and hypoxia
PC12 cells transfected with Bcl-2 and the control vector were described
previously (Shimizu et al., 1996a). PC12 and HeLa cells were maintained
in RPMI 1640 medium with 10% FBS, whereas MEF and CHO-k1 cells
were cultured in DME with 10% FBS. 8.0   10
5 cells were seeded in 3.5-
cm dishes. After the cells became attached to the dishes, the medium was
changed to DME with 2.2 g/l glucose and 10% dialyzed FBS, and the cells
were exposed to normoxia or hypoxia at 37 C. Hypoxia was achieved by
using a BBL GasPak Plus™ in an anaerobic jar (Becton Dickinson), and the
atmosphere was monitored by the white color of indicator strips (BBL). Af-
ter trypsinization, cells were collected and resuspended in PBS. After stain-
ing with 10  M Hoechst 33342, nuclear changes were assessed under a
fluorescence microscope (model BX50; Olympus). Cerebellar granule neu-
rons were prepared as described previously (Tanabe et al., 1997). In brief,
the cerebellum was removed from 7-d-old mice, digested with trypsin and
DNase I, and cells were plated on poly-D-lysine–coated dishes. After elim-
ination of nonneuronal cells by incubation with cytosine arabinofranoside,
cells were grown for 7 d in DME containing 10% horse serum and 25 mM
KCl. Cell death was induced by changing the medium to serum-free DME
containing 5 mM KCl.
Caspase activity
PC12 cells were harvested and suspended in buffer A as described below.
Caspase activity was measured as described previously (Shimizu et al.,
1996b).
Cell-free system
HeLa cells were attached to 12-well slide glasses. After washing twice
with transportation buffer (TB; 20 mM Hepes-KOH, pH 7.3, 110 mM
CH3COOK, 2 mM (CH3COO)2 Mg, and 0.5 mM sodium EGTA), cells were
incubated with TB containing 20  g/ l digitonin and 2 mM DTT for ex-
actly 3 min at RT. After washing twice with TB containing 2 mM DTT, per-
meabilized cells were incubated with 30  l cell lysates for 2 h at 37 C.
Nuclear changes were assessed under a fluorescence microscope after
staining with 10  M Hoechst 33342. To prepare PC12 cell lysates, cells
were cultured in a hypoxic or normoxic atmosphere for 24 h. Then, the
cells were harvested and suspended in buffer A (5 mM Hepes-KOH, pH
7.3, 10 mM CH3COOK, 2 mM (CH3COO)2 Mg, 0.5 mM sodium EGTA,
and 1 mM DTT) supplemented with 0.1 mM PMSF, 10  g/ml pepstatin, 10
 g/ml leupeptin, and 10  g/ml aprotinin. Cells were homogenized and
sonicated. After centrifugation at 39,000 rpm for 1 h, the supernatant was
used for the nuclear shrinkage assay. Mitochondrial supernatant was pre-
pared as described previously (Shimizu et al., 1998). In brief, isolated rat
liver mitochondria were incubated with 50  M Ca
2  for 30 min. After cen-
trifugation at 15,000 rpm for 5 min, the supernatant was used for the nu-
clear shrinkage assay. The rat liver S100 fraction was prepared as de-
scribed below.
Purification of nuclear shrinkage factor
All purification steps were performed at 4 C. Livers from 25 male rats were
perfused with PBS via the portal vein and were homogenized in 5 vol of
buffer A (supplemented with 0.1 mM PMSF, 10  g/ml pepstatin, 10  g/ml
leupeptin, and 10  g/ml aprotinin) using a motorized homogenizer. The
homogenates were centrifuged at 39,000 rpm for 1 h in a rotor (60Ti;
Beckman Coulter) to obtain the supernatant (the S100 lysate). After filtering
through a 0.45- m filter (MILLEX-HA; Millipore), the S100 lysate was
loaded onto a 50-ml heparin Sepharose column and the flow-through frac-
tions were pooled. The pooled fractions were loaded onto a 50-ml Hi-
Trap™ Q Sepharose column equilibrated with buffer A, then was eluted
with a 600-ml linear salt gradient (0–0.25 M NaCl), and 15-ml fractions
were collected. The active fractions (0.16–0.22 M NaCl) were pooled, 1 M
ammonium sulfate was added directly, and the precipitate was removed
by centrifugation. The resulting supernatant was loaded on a 25-ml butyl
Sepharose column, followed by washing with buffer A containing 0.5 M
ammonium sulfate and subsequent elution with buffer A. Active fractions
(75 ml) were pooled, and directly loaded onto a 10-ml hydroxyapatite col-
umn equilibrated with 0.01 M potassium phosphate (pH 6.8), followed by
washing with 0.25 M potassium phosphate (pH 6.8) and elution with a 30-
ml linear gradient (0.25–1.0 M) of potassium phosphate. The active frac-
tions (7 ml) were directly loaded onto a 5-ml chelating Sepharose column
charged with 0.1 M Co
2 , and eluted with 0.02 M Na2PO4, pH 7.2, 0.5 M
NaCl, and 0.05 M EDTA. The active fractions were concentrated and
loaded onto a 24-ml Superdex™ 200 gel filtration column equilibrated
with buffer A containing 0.05 M NaCl. Active fractions (1 ml, 15.3  g)
were loaded onto a 0.24-ml Mini Q™ Sepharose column equilibrated with
buffer A containing 0.05 M NaCl. Proteins bound to the column was
eluted with a 0.9-ml linear NaCl gradient (0.05–0.25 M NaCl), and 50  l
fractions were collected. These fractions (0.075–0.2 M NaCl) were used
for nuclear shrinkage analysis and for SDS-PAGE with silver staining. All of
the equipment and column resins for purification were purchased from
Amersham Biosciences. After lysyl endopeptidase digestion and reverse
HPLC, peptide sequences were determined by AproScience Co.
Degenerative PCR
The degenerative PCR primers including inosine (I) were designed from
four peptides. The single-letter designation for each combination of nucle-
otides was as follows: R (A or G), S (G or C), H (A, C, or T), N (A, G, C, or
T), Y (C or T), M (A or C), W (A or T), and D (A, G, or T).
The peptides and their primers are listed as follows: peptide 1 D/AVY-
FATGLQEE: sense primer 1 5 -GMIGTITAYTTYGCIACIGG-3 , sense primer
2 5 -TAYTTYGCIACIGGIYTICARG-3 , antisense primer 1 5 -YTCYTCYT-
GIARICCIGTIGC-3 , antisense primer 2 5 -ARICCIGTIGCRAARTAIAC-3 ;
peptide 2 PFPEVSEDQLK: sense primer 1 5 -CCITTYCCIGARGTIWSI-
GARG-3 , sense primer 2 5 -GAIGTIISIGARGAYCARYT-3 , antisense
primer 1 5 -TTIAIYTGRTCYTCISWIAC-3 , antisense primer 2 5 -YTGRTCIT-
CISWIACYTCIGG-3 ; peptide 3 QFALGDGTGEF: sense primer 1 5 -CART-
TYGCIYTIGGICCIGG-3 , sense primer 2 5 -GCIYTIGGICCIGGNACNGG-
3 , antisense primer 1 5 -RAAYTCICCIGTICCIGGNCC-3 , antisense primer
2 5 -CCIGGICCIARIGCRAAYTG-3 ; peptide 4 MAEIIQNWNEI: sense
primer 1 5 -ATGGCIGARATHATHCARAA-3 , sense primer 2 5 -RATIATIC-
ARAAYTGGAAYG-3 , antisense primer 1 5 -DATITCITTCCARTTYTGDA-
3 , and antisense primer 2 5 -CARTTITGIATDATYTCNGC-3 
Template cDNA was synthesized from total rat liver RNA using reverse
transcriptase and oligo dT. cDNA was amplified with every combinationPLA2 induces nuclear shrinkage | Shinzawa and Tsujimoto 1229
of sense and antisense primer 1 by PCR (94 C for 3 min and 30 cycles of
94 C for 30 s, 45 C for 30 s, and 72 C for 1 min). PCR products were di-
luted and amplified with each combination of sense and antisense primer
2 under the same conditions. The amplified products were cloned into the
pGEM-T vector (Promega), and the nucleotide sequence was determined.
Measurement of the nuclear area
After staining of the nucleus with 10  M Hoechst 33342, the fluorescence
image was recorded using a digital CCD camera (model C303; Olympus).
Then the area of each nucleus was measured with Quantity One software
(Bio-Rad Laboratories).
PLA2 activity
A mixture of DPPS (1,2-dipalmitoylphosphatidylserine), cholesterol, phos-
phatidylglycerol, and PED6 (107:31:20:1; a total of 287 nmol) was dried
and resuspended in 1 ml PBS, and liposomes were prepared by sonication
on ice for 5 min. Then, the liposomes were added to cultures at a concen-
tration of 50  l/ml of medium and incubation was done for 10 min at
37 C. The cells were washed with PBS, stained with 10  M Hoechst
33342, and placed on a glass slide. Then, fluorescence was visualized us-
ing a confocal microscope (model 510; Carl Zeiss MicroImaging, Inc.). In
the experiment shown in Fig. 6 B, cells were treated with the liposome (50
 l/ml) for 1 min and collected by centrifugation. The cells were resus-
pended in PBS and disrupted by freezing at  80 C and thawing, followed
by sonication. Fluorescence intensity was measured using a spectrofluo-
rometer with excitation at 485 nm and emission at 525 nm.
AA release assay
Cells were labeled for 24 h with 0.1  Ci/ml [
3H]AA in serum-free DME con-
taining 0.2% (wt/vol) fatty acid-free BSA. After washing three times with
DME, the cells were exposed to hypoxia for 36 h. After centrifugation, the
radioactivity of the supernatant was measured using a scintillation counter.
LDH release
LDH released into the culture medium was determined using a commer-
cial LDH assay kit (Wako Pure Chemical Industries, Ltd.).
Cell fractionation
CHO-k1 cells exposed to hypoxia or normoxia were homogenized in hy-
potonic buffer (10 mM Tris-Cl, pH 7.8, 150 mM NaCl, and 1 mM EDTA)
containing 0.1% Triton X-100. The lysates were centrifuged at 3,000 rpm
for 10 min at 4 C and separated into pellet and supernatant fractions. The
pellet fraction was resuspended in hypotonic buffer containing 0.1% Tri-
ton X-100, recentrifuged, and used as the nuclear fraction. The supernatant
fraction was recentrifuged at 15,000 rpm for 20 min at 4 C and was used
as the cytosolic fraction.
Western blot analysis and immunohistochemistry of iPLA2
Immunoblot analysis was performed with an HRP-conjugated secondary anti-
body using ECL Western blotting detection reagents (Amersham Biosciences).
For immunohistochemistry, CHO-k1 cells were cultured in a glass-bottomed
chamber. After exposure to hypoxia for 36 h, the cells were fixed with 2%
PFA and 0.1% Triton X-100. After washing with PBS, the cells were incubated
with polyclonal anti-iPLA2 antiserum, and then with biotin-conjugated anti–
rabbit IgG and streptavidin rhodamine. Fluorescence was visualized using a
confocal microscope (model 510, Carl Zeiss MicroImaging, Inc.).
siRNA
siRNA for GFP and iPLA2  mRNA was obtained from Dharmacon Re-
search, Inc. The targeted region of GFP and hamster iPLA2  cDNA was
5 -GGCTACGTCCAGGAGCGCACC-3  and 5 -AACGTGTTCGAGAG-
GAAGGGC-3 , respectively. Transfection of siRNA into CHO-k1 cells in
6-well dishes was performed with siFECTOR (B-Bridge International, Inc.)
according to the supplier’s protocol. In brief, 6  g siFECTOR was diluted
in 100  l Opti-MEM
®, mixed with 2, 4, or 6  g siRNA diluted in 100  l of
Opti-MEM
®, and incubated for 15 min. Then, the whole mixture was
added to cells in the culture medium (serum-free DME) in one well of a
6-well dish. After 10 h of incubation, 2 ml DME supplemented with 10%
FBS was added to each well, and the cells were incubated for another 16 h.
This transfection procedure was repeated three times before performing
immunoblotting and hypoxia treatment.
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